Loading...
XNASBLACU
Market cap48mUSD
Nov 29, Last price  
11.89USD
Name

Bellevue Life Sciences Acquisition Corp

Chart & Performance

D1W1MN
XNAS:BLACU chart
P/E
119.00
P/S
—
EPS
0.10
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
404k
P
-23,812-3,308-35,388403,780
CFO
-819k
L+19,233.32%
-23,812-461-4,235-818,766

Profile

Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.
URL
IPO date
Feb 10, 2023
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
1,831
35
Unusual Expense (Income)
NOPBT
(1,831)
(35)
NOPBT Margin
Operating Taxes
541
(228)
Tax Rate
NOPAT
(2,372)
193
Net income
404
-1,241.01%
(35)
969.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
27,974
(683)
BB yield
-47.38%
Debt
Debt current
1,200
Long-term debt
Deferred revenue
Other long-term liabilities
2,070
1,234
Net debt
(36,621)
1,075
Cash flow
Cash from operating activities
(819)
(4)
CAPEX
Cash from investing activities
(33,830)
Cash from financing activities
34,539
124
FCF
(880)
(109)
Balance
Cash
15
125
Long term investments
36,605
Excess cash
36,621
125
Stockholders' equity
32,519
(62)
Invested Capital
2,070
1,225
ROIC
23.41%
ROCE
EV
Common stock shares outstanding
5,623
9,055
Price
10.50
 
Market cap
59,041
 
EV
22,420
EBITDA
(1,831)
(35)
EV/EBITDA
Interest
Interest/NOPBT